Conditions: Atypical Hemolytic-Uremic Syndrome
Keywords: Atypical Hemolytic-Uremic Syndrome
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 22
Healthy volunteers: no

Brief summary:
The primary purpose is to assess the efficacy and safety of eculizumab in pediatric patients with aHUS to control TMA as characterized by thrombocytopenia, hemolysis and renal impairment.

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: Eculizumab
Intervention descriptions: intervention 1: Fixed dosing is based on body weight cohorts. Adjustment of dose to accommodate patient growth is possible.

Protocol document: